PSUSA/00000796/202505
Submitted by Anonymous (not verified) on 21 January 2026 - 11:57
PSUSA/00000796/202505
PSUSA/00010881/202506
Submitted by Anonymous (not verified) on 21 January 2026 - 11:57
PSUSA/00010881/202506
PSUSA/00000276/202506
Submitted by Anonymous (not verified) on 21 January 2026 - 11:57
PSUSA/00000276/202506
PSUSA/00002769/202506
Submitted by Anonymous (not verified) on 21 January 2026 - 11:57
PSUSA/00002769/202506
Carmen Purdel elected as new chair of the Committee for Herbal Medicinal Products
Submitted by Anonymous (not verified) on 21 January 2026 - 9:13
Carmen Purdel elected as new chair of the Committee for Herbal Medicinal Products
Questions and answers about the clinical study data proof-of-concept pilot for industry
Submitted by Anonymous (not verified) on 21 January 2026 - 8:30
Questions and answers about the clinical study data proof-of-concept pilot for industry
Questions and Answers on the 'OPEN' Framework
Submitted by Anonymous (not verified) on 20 January 2026 - 22:46
Questions and Answers on the 'OPEN' Framework
Human medicines European public assessment report (EPAR): Ponlimsi, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 20 January 2026 - 16:36
Human medicines European public assessment report (EPAR): Ponlimsi, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 20 January 2026 - 16:32
Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 13, Status: Authorised
Human medicines European public assessment report (EPAR): Nyvepria, pegfilgrastim, Date of authorisation: 18/11/2020, Revision: 9, Status: Authorised
Submitted by Anonymous (not verified) on 20 January 2026 - 16:25
Human medicines European public assessment report (EPAR): Nyvepria, pegfilgrastim, Date of authorisation: 18/11/2020, Revision: 9, Status: Authorised